EURX Eurand N.V. featured news, full reports, and detailed charts
Eurand N.V. (EURX) Wrap Up:
We are a holding company named Eurand N.V. (formerly known as Eurand B.V., and before that, Eurand Pharmaceuticals Holdings B.V.) and were incorporated in The Netherlands as a private company with limited liability in 1984. We were converted into a Dutch public limited liability company by notarial deed of conversion executed November 30, 2006. In May 2007, we completed an initial public offering of our ordinary shares in the United States and our ordinary shares began trading on the NASDAQ Global Market. Our principal executive offices are located at Olympic Plaza, Fred. Roeskestraat 123, 1076 EE Amsterdam, The Netherlands, telephone +31 20-673 2744. We have operating subsidiaries organized in the United States, Italy, France and Ireland. A list of our subsidiaries as of December 31, 2007 is set forth in Exhibit 8 to this Annual Report on Form 20-F. ... More..."http://secfilings.nasdaq.com/edgar_conv_html%2f2008%2f03%2f31%2f0000893220-08-000964.html#FIS_COMPANY_INFORMATION"www.eurand.com
526 Employees
Founded in 1984
Eurand N.V. (EURX:NASDAQ)
LAST $12.63 USD
CHANGE TODAY -0.03 -0.24%
VOLUME 27.9K
As of 3:59 PM 11/20/09 All times are local (Market data by Reuters is delayed by at least 15 minutes).
Snapshot of Eurand N.V. (EURX)
|
OPEN
$12.63
|
PREVIOUS CLOSE
$12.66
|
|
|
DAY HIGH
$12.75
|
DAY LOW
$12.63
|
|
|
52 WEEK HIGH
08/28/09 - $15.53
|
52 WEEK LOW
12/1/08 - $6.17
|
|
|
MARKET CAP
604.3M
|
AVERAGE VOLUME 3 mo
90.7K
|
|
|
DILUTED EPS TTM
$-0.15
|
SHARES OUTSTANDING
47.8M
|
|
|
EURX Does Not Pay Dividends
|
P/E TTM
NM
|
|
| K = Thousands M = Millions B = Billions | ||
EURX Top Compensated Officers
Mr. Gearóid M. Faherty
Chairman and Chief Executive Officer
Age: 49
Total Annual Compensation: €771.7K
Executives, Board Directors
Compensation as of Fiscal Year 2008.
Key developments for Eurand N.V. (EURX)
Eurand N.V. Reports Consolidated Earnings Results for the Third Quarter and Nine Months Ended September 30, 2009
11/5/2009
Eurand N.V. reported consolidated earnings results for the third quarter and nine months ended September 30, 2009. For the quarter, the company reported total revenues were EUR 30.6 million ($44.8 million), an increase of 25%, or 19% at constant currency rates, from the third quarter of 2008. The increase in revenues for the 2009 third quarter was led by strong sales of Eurand's unbranded pancreatic enzyme product, Pancrelipase, currently the second-most prescribed coated PEP with a 21.2% share of total prescriptions dispensed through October 23, 2009. Operating income was EUR 0.4 million ($0.6 million) versus operating income of EUR 22.5 million ($32.9 million) for the comparable period of 2008. Net loss was EUR 0.4 million ($0.6 million) or EUR 0.01 per fully diluted share ($(0.01) per share) compared to EUR 20.2 million ($29.6 million), or EUR 0.43 per fully diluted share ($0.63 per share). Income before taxes was EUR 527,000 against EUR 22.6 million for the same quarter a year ago period. For the nine-month period, the company reported total revenues were EUR 90.3 million ($132.1 million), an increase of approximately 24%, or 15% at constant currency rates, compared with the same period of 2008. The increase in revenues can be attributed primarily to sales of Pancrelipase and sales of ULTRASE to Axcan, to higher royalties, notably from AMRIX by Cephalon, and to higher development fees. Operating income was EUR 1.2 million ($1.8 million) compared to EUR 20.1 million ($29.4 million). Net loss was EUR 2.0 million ($2.9 million) or EUR (0.04) per fully diluted share ($(0.06) per share). Net income was EUR 16.4 million ($24.0 million), or EUR 0.35 per fully diluted share ($0.52 per share), for the first nine months of 2008. Income before taxes was $1.2 million against $20.5 million for the same period a year ago.
Eurand N.V. - Conference Presentation Call
10/28/2009
Eurand N.V. - Conference Presentation Calls
Eurand Prices Ordinary Shares Offering; Seeks Acquisitions
10/22/2009
Eurand N.V announced the pricing of its previously disclosed public offering of 8,500,000 ordinary shares at an initial price to the public of $11.25 per share. Of the 8,500,000 shares being offered, 2,000,000 are newly issued by Eurand N.V., and the remaining 6,500,000 are currently issued and outstanding. The proceeds from the sale of 2,000,000 ordinary shares will be utilized for potential product acquisitions and/or potential acquisitions of complementary businesses and research and development of additional product candidates, as well as to fund working capital and other general corporate purposes.
EURX Competitors
| Company | Last | Change |
| Elan Corporation | €4.36 EUR | +0.039 |
| Penwest Pharmaceuticals Co | $2.28 USD | +0.01 |
| Skyepharma | 95.50 GBX | +0.50 |
| Watson Pharmaceuticals Inc | $35.15 USD | -0.38 |
| Market data is delayed at least 20 minutes. | ||
Industry Analysis
| Valuation | EURX | Industry Range |
| Price/Earnings | NM | Not Meaningful |
| Price/Sales | 3.4x |
|
| Price/Book | 3.9x |
|
| Price/Cash Flow | NM | Not Meaningful |
| TEV/Sales | 3.4x |
|
|
EURX |
||
|
More Recent News About Eurand N.V.
More news for EURX
Eurand, shareholders offering 8.5 million shares
Copyright © 2009 Yahoo! All rights reserved. Privacy Policy - Terms of Service - Copyright Policy - Report Problems Quotes and other information supplied by independent providers identified on the Yahoo! Finance partner page. Quotes are updated automatically, but will be turned off after 25 minutes of inactivity. Quote data delayed 15 minutes for Nasdaq, NYSE and Amex. Real-Time continuous streaming quotes are available through our premium service. You may turn streaming quotes on or off. All information provided "as is" for informational purposes only, not intended for trading purposes or advice. Yahoo! is not an investment adviser and does not provide, endorse or review any information or data contained herein....Click here to read the whole Article (external link)
Neurogenic Orthostatic Hypotension Treatment Should Pass Phase III Trials: Catalyst For Biotech Stock Says Wedbush Morgan Analyst
67 WALL STREET, New York - October 20, 2009 - The Wall Street Transcript has just published its Biotechnology Report offering a timely review of the sector to serious investors and industry executives. This 70 page feature contains expert industry commentary through in-depth interviews with public company CEOs, Equity Analysts and Money Managers. The full issue is available by calling (212) 952-7433 or via The Wall Street Transcript Online. Topics covered: Heightened M&A Activity - Trend Toward Orphan Disease Drug Development - Generic Drug Competition - Current Length Of FDA Approval Process - Ownership Ego Preventing Shareholder Returns - IPO And Secondary Offering Window Opening - Big Pharma R&D Pipeline - Decreased Clinical Development Risk - Impact Of Health Care Reform - Convergence Of Large-Cap Biotech And Pharmaceutical Companies - Easier Credit For Small Cap Biotech Companies - Developments In Cancer Chemotherapeutics - Gene Delivery Technology Companies include: ADVENTRX (ANX); Abbott Labs (ABT); Advaxis (ADVX); Amedisys (AMED); Amgen (AMGN); Amylin Pharmaceuticals (AMLN); Antares Pharma (AIS); BioDelivery Sciences (BDSI); Biogen Idec (BIIB); Biomarin (BMRN); Boston Scientific (BSX); Bristol Myers (BMY); CVS Caremark (CVS); Celgene (CELG); Cerner (CRN); Cerus (CERS); Coke (KO); CombiMatrix (CBMX); Coventry Health Care (CVH); DARA (DARA); Eisai (ESALY); Eli Lilly (LLY); GenVec (GNVC); Gilead (GILD); GlaxoSmithKline (GSK); Health Management Associates (HMA); Human Genome Sciences (HGSI); Inspire Pharmaceuticals (ISPH); Intellect Neurosciences (ILNS.OB); InterMune (ITMN); International Stem Cel...Click here to read the whole Article (external link)
IPOs Looking Iffy
Six secondary offerings price, but IPOs still look iffy. HUGE offerings of IPOs and secondaries still waiting. 6 secondaries priced this morning, and the good news is every single one of them is trading above the secondary pricing at midday: The bad news is buyers of IPOs are holding their noses at some of the recent offerings. Example: AGA Medical Holdings [AGAM Loading...   (...Click here to read the whole Article (external link)
Eurand Announces Pricing of Offering of Ordinary Shares
AMSTERDAM, THE NETHERLANDS--(Marketwire - 10/22/09) - Eurand N.V. (NASDAQ:EURX - News), a global specialty pharmaceutical company, today announced the pricing of its previously disclosed public offering of 8,500,000 ordinary shares at an initial price to the public of $11.25 per share. The shares are being offered through an underwriting syndicate led by Deutsche Bank Securities and BofA Merrill Lynch, together with co-managers Cowen and Company and Thomas Weisel Partners. The offering is expected to close on or about October 27, 2009. Of the 8,500,000 shares being offered, 2,000,000 are newly issued by Eurand N.V., and the remaining 6,500,000 are currently issued and outstanding. The Company intends to use the net proceeds from the sale of its 2,000,000 ordinary shares to fund potential product acquisitions and/or potential acquisitions of complementary businesses and research and development of additional product candidates, as well as to fund working capital and other general corporate purposes.Eurand Chairman and Chief Executive Officer Gear�id Faherty, the Company's second-largest shareholder, has elected not to sell any shares in this offering. The other selling stockholders will increase their sale of shares so that the total offering size remains 8,500,000 shares. Those selling stockholders also have granted the underwriters an option to purchase an additional 1,275,000 ordinary shares at the public offering price to cover over-allotments, if any.The offering may be made only by means of a prospectus. Copie...Click here to read the whole Article (external link)
Eurand Reports Key Achievements and Strong Revenue Growth for Third Quarter 2009
AMSTERDAM, THE NETHERLANDS--(Marketwire - 11/05/09) - Eurand N.V. (NASDAQ:EURX - News) Key Achievements:� -- Received U.S. Food and Drug Administration (FDA) approval for lead proprietary product ZENPEP(TM) (pancrelipase) Delayed-Release Capsules, a pancreatic enzyme product (PEP) for the treatment of exocrine pancreatic insufficiency (EPI) due to cystic fibrosis (CF) or other conditions; launch is expected to commence by the end of November 2009 -- Grew third quarter 2009 revenues 25%, or 19% at constant currency rates, to EUR 30.6 million ($44.8 million) compared with the same period in 2008 -- Continued to grow revenues from Pancrelipase, Eurand's unbranded PEP, which held 21.2% of all prescriptions for coated PEPs for the week ended October 23, 2009, according to IMS Health Incorporated -- Increased total cash, cash equivalents and marketable securities to EUR 31.3 million ($45.8 million) at September 30, 2009, up EUR 8.6 million ($12.5 million) from December 31, 2008 -- On October 27th, 2009, completed a public offering of 9,775,000 ordinary shares at $11.25 per share, including 2,000,000 newly issued shares and exercise of over-allotment option of 1,275,000 shares. The net proceeds of approximately $20.6 million from the sale of the newly issued shares will add substantially to the Company's cash reserves. Eurand N.V. (NASDAQ:...Click here to read the whole Article (external link)
Eurand to Participate in Upcoming Investor Conferences
Copyright © 2009 Yahoo! All rights reserved. Privacy Policy - Terms of Service - Copyright Policy - Report Problems Quotes and other information supplied by independent providers identified on the Yahoo! Finance partner page. Quotes are updated automatically, but will be turned off after 25 minutes of inactivity. Quote data delayed 15 minutes for Nasdaq, NYSE and Amex. Real-Time continuous streaming quotes are available through our premium service. You may turn streaming quotes on or off. All information provided "as is" for informational purposes only, not intended for trading purposes or advice. Yahoo! is not an investment adviser and does not provide, endorse or review any information or data contained herein....Click here to read the whole Article (external link)
Q3 2009 EURAND N V Earnings Release - 07:00 am ET
Earnings Announcements for Thursday, November 5CompanySymbolTimeConferenceCall21st Century HoldingTCHC2:00 pm ET3I INFRASTRUCTURE3IN.LBefore Market OpenAbiomed, Inc.ABMDBefore Market OpenListenABOVENET INCABVTAfter Market CloseListenAbraxis BioScience, Inc.ABIIBefore Market OpenListenAccelrys Inc.ACCLAfter Market CloseListenACI Worldwide, Inc.ACIWBefore Market OpenACTIONS SEMICONDUCTOR CO LTDACTSAfter Market CloseActive Biotech ABACTI.STTime Not SuppliedActivision Blizzard, Inc.ATVIAfter Market CloseAdecco SAAHEXF.PK01:00 am ETAinsworth Lumber Company Ltd.ANS.TOAfter Market CloseAir MethodsAIRMAfter Market CloseAker ASAAKERTime Not SuppliedALAMOS GOLD INCAGI.TOBefore Market OpenAlaska Communications Systems GroupALSKAfter Market CloseAlexandria Real Estate...Click here to read the whole Article (external link)
Eurand N.V. Q3 2009 Earnings Conference Call
Eurand N.V. (EURX) Q3 2009 Earnings Call November 5, 2009 08:30 a.m. ET Executives Bill Newbould - VP, IR Gearóid Faherty - Chairman and CEO Mario Crovetto - CFO Analysts Annabel Samimy - Thomas Weisel John Newman - Oppenheimer Frank Pinkerton - SunTrust Scott Henry - Roth Capital Rich Silver - Barclays Capital Scott Hirsch - Credit Suisse Greg Gilbert - Bank of America Merrill Lynch David Steinberg - Deutsche Bank Presentation Operator Greetings ladies and gentlemen and welcome to the Eurand third quarter 2009 financial results conference call. At this time all participants are in a listen-only mode. A question-and-answer session will follow the formal presentation. (Operator Instructions) It is now my pleasure to introduce your host, Mr. Bill Newbould, Vice President, Investor Relations at Eurand. Thank you Mr. Newbould, you may now begin. Bill Newbould Thank you operator and good morning everyone. Joining us on the call today are Gearóid Faherty, Chairman and Chief Executive Officer and Mario Crovetto, Chief Financial Officer. Before we begin I’d like to remind everybody that this conference call today may contain forward-looking statements within the meaning of the Federal Securities Laws These statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from the results, performance or achievements expressed or implied by such forward-looking statements. Factors that could cause our actual results and outcomes to differ materially from those expressed in or implied by such forward-looking state...Click here to read the whole Article (external link)
Phase II/III Clinical Study Compares Safety and Efficacy of Two Doses of ZENPEP(TM) (Pancrelipase) Delayed-Release Capsules for Fat Absorption in Adult Chronic Pancreatitis Patients With Exocrine Pancreatic Insufficiency
PHILADELPHIA, PA--(Marketwire - 11/13/09) - Eurand N.V. (NASDAQ:EURX - News), a global specialty pharmaceutical company, today announced data from a Phase II/III clinical study demonstrating that ZENPEP(TM) (pancrelipase) Delayed-Release Capsules significantly improves fat absorption in patients with exocrine pancreatic insufficiency (EPI) due to chronic pancreatitis. EPI is a serious condition associated with a number of diseases including cystic fibrosis (CF), chronic pancreatitis (CP), pancreatic cancer, gastrointestinal surgery and other conditions. Patients suffering from EPI are unable to adequately produce or secrete pancreatic enzymes necessary for digestion, resulting in the malabsorption of nutrients and overall malnutrition."EPI due to chronic pancreatitis can result in malnutrition and GI symptoms that negatively affect quality of life for these patients," said Dr. Phillip Toskes, Professor of Medicine in the Division of Gastroenterology, Hepatology and Nutrition at the University of Florida College of Medicine. "The safety and efficacy benefits of ZENPEP for chronic pancreatitis patients with EPI are clearly demonstrated in this study. Even the lower dose of ZENPEP was found to be beneficial to improve fat and protein absorption and reduce EPI symptoms."Ruth Thieroff-Ekerdt, M.D., Eurand's Chief Medical Officer, said, "This study provides exciting new data on the benefit of ZENPEP across the spectrum of disease severity in EPI due to CP. We are delighted that we can share with physicians these positive res...Click here to read the whole Article (external link)
Would you like to leave a comment about Eurand N.V. EURX
Find out what social network information about Eurand N.V. are available on RealpenniesWorst 5 - Click here to find out what stocks have been voted down by our visitors and users
Besides Eurand N.V. there is more great information available at Realpennies.com